[ad_1]
Novartis has boosted its 2024 outlook for a second time this year, thanks to strong sales for some of its biggest drugs used to treat heart failure and other ailments.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...